885 terminated. 885 Phase 1, 328 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 885 | Terminated 885 |
| Phase 2 | 328 | Terminated 328 |
Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL Antigen-specific T cells CAR-T/CTL and DCvac - T-Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2026-06-01 | 2026-11-03 |
| Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease Pociredir - Sickle Cell Disease | Phase 1 | Terminated | Fulcrum Therapeutics | 13 | 2025-12-13 | 2026-06-18 |
| Multiple CAR-T Cell Therapy Targeting AML CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2025-08-01 | 2026-11-02 |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-08-01 | 2026-10-30 |
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Pfizer | 6 | 2025-05-08 | 2026-05-08 |
| A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus YTS109 cell injection - Lupus Nephritis (LN), Immune Thrombocytopenia (ITP) | Phase 1 | Terminated | China Immunotech (Beijing) Biotechnology Co., Ltd. | 2 | 2025-04-16 | 2026-10-14 |
| A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia CD19 t-haNK - B-ALL, Leukemia | Phase 1 | Terminated | ImmunityBio, Inc. | 4 | 2025-04-11 | 2026-08-19 |
| A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML S227928, Venetoclax - Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML | Phase 1 / Phase 2 | Terminated | Servier Bio-Innovation LLC | 13 | 2025-02-25 | 2026-03-30 |
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult | Phase 1 / Phase 2 | Terminated | BlueSphere Bio, Inc | 2 | 2025-02-04 | 2026-09-10 |
| Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 BL-M11D1 - Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Terminated | SystImmune Inc. | 52 | 2024-12-19 | 2026-09-24 |
| ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Terminated | University of Washington | 1 | 2024-12-18 | 2025-07-29 |
| A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) AUR104 - Select Relapsed/Refractory Lymphoid Malignancies | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 9 | 2024-12-12 | 2026-04-17 |
| BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B BE-101 - Hemophilia B, Hemophilia B, Moderately Severe or Severe | Phase 1 / Phase 2 | Terminated | Be Biopharma | 5 | 2024-12-04 | 2026-06-15 |
| Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) Venetoclax, Azacitidine, Donor Lymphocyte Infusion - Acute Myeloid Leukemia | Phase 1 | Terminated | Antonio M Jimenez Jimenez | 2 | 2024-12-04 | 2026-07-13 |
| Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML Luveltamab tazevibulin - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Terminated | Sutro Biopharma, Inc. | 1 | 2024-12-04 | 2026-10-13 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia NMS-03597812 - Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Terminated | Nerviano Medical Sciences | 23 | 2024-10-16 | 2026-11-19 |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Terminated | Centre Leon Berard | 1 | 2024-09-11 | 2025-02-20 |
| Study of Tazemetostat in Lymphoid Malignancies Tazemetostat - T-cell Lymphoma | Phase 1 | Terminated | University of Alabama at Birmingham | 6 | 2024-09-05 | 2026-04-17 |
| A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies SAR443579, venetoclax, azacitidine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Sanofi | 7 | 2024-08-13 | 2026-10-19 |
Showing 20 of 885. Sign in to see all of them.
Leukemia, Myeloid, Acute (290) · Multiple Myeloma (213) · Leukemia, Lymphocytic, Chronic, B-Cell (154) · Leukemia (145) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (132) · Myelodysplastic Syndromes (131) · Recurrence (109) · Lymphoma, Non-Hodgkin (96) · Lymphoma (85) · Lymphoma, Large B-Cell, Diffuse (68) · Lymphoma, Mantle-Cell (63) · Lymphoma, Follicular (59) · Hematologic Neoplasms (58) · Neoplasms (57) · Burkitt Lymphoma (51)
Hemic and Lymphatic Diseases (885) · Neoplasms by Histologic Type (724) · Neoplasms (706) · Immune System Diseases (497) · Immunoproliferative Disorders (469) · Lymphoproliferative Disorders (463) · Leukemia (400) · Pathological Conditions, Signs and Symptoms (344) · Pathologic Processes (340) · Disease Attributes (321) · Leukemia, Myeloid (319) · Lymphatic Diseases (314) · Hemorrhagic Disorders (272) · Cardiovascular Diseases (247)
Dexamethasone (68) · Cyclophosphamide (63) · Cytarabine (58) · fludarabine (56) · Azacitidine (54) · venetoclax (43) · Rituximab (38) · Lenalidomide (37) · Bortezomib (33) · fludarabine phosphate (30) · Calcium Dobesilate (29) · Filgrastim (23) · Decitabine (18) · Melphalan (17) · pomalidomide (17)
M.D. Anderson Cancer Center (53) · National Cancer Institute (NCI) (49) · Novartis Pharmaceuticals (18) · Celgene (17) · Fred Hutchinson Cancer Center (14) · Gilead Sciences (14) · AbbVie (13) · Amgen (12) · Masonic Cancer Center, University of Minnesota (12) · Incyte Corporation (11) · Washington University School of Medicine (11) · GlaxoSmithKline (10) · Northwestern University (9) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (9) · Bristol-Myers Squibb (8)
United States (735) · Spain (89) · France (76) · Italy (57) · Canada (54) · Australia (52) · Germany (52) · United Kingdom (47) · China (40) · Netherlands (27) · South Korea (26) · Japan (25) · Belgium (24) · Israel (24) · Poland (13)
Roger Strair, MD, PhD (4) · Farhad Ravandi-Kashani, MD (3)
PMID 34398557, PMID 23400739, PMID 31215818, PMID 31527168, PMID 33197925, PMID 35857660, PMID 36841672, PMID 17151364, PMID 18297527, PMID 18550886, PMID 19010875, PMID 19029442, PMID 19139736, PMID 19503090, PMID 19840322, PMID 20117846, PMID 20460644, PMID 20563869, PMID 20644039, PMID 20732454, PMID 20797926, PMID 20936416, PMID 21145590, PMID 21494838, PMID 22080439, PMID 22080968, PMID 22448921, PMID 22987312, PMID 23092873, PMID 23233571, PMID 23256542, PMID 23393050, PMID 23682558, PMID 23829485, PMID 23887852, PMID 23973010, PMID 24200998, PMID 24241210, PMID 24276047, PMID 24355079, PMID 24615776, PMID 24615777, PMID 24615778, PMID 25441108, PMID 25655379, PMID 25824692, PMID 26139427, PMID 26384354, PMID 26472751, PMID 26675348
2018 (16), 2017 (12), 2019 (12), 2023 (12), 2014 (8), 2016 (7), 2015 (6), U01CA076576 (6), P30CA015083 (5), P30CA016672 (5), P30CA015704 (4), P30CA072720 (4), 2008 (3), N01CM62203 (3), P01CA018029 (3)